Agile Therapeutics Inc financial data

Symbol
AGRX on Nasdaq, AGXRW on OTC
Industry
Pharmaceutical Preparations
Location
500 College Road East, Suite 310, Princeton, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 57.6 % -25.9%
Quick Ratio 15.2 % +43.4%
Debt-to-equity -191 % +68.6%
Return On Equity 60.9 % -88.3%
Return On Assets -67.3 % +34.7%
Operating Margin -74.1 % +78.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.86M shares -85.3%
Common Stock, Shares, Outstanding 6.86M shares +636%
Entity Public Float 4.8M USD -66.7%
Common Stock, Value, Issued 5K USD
Weighted Average Number of Shares Outstanding, Basic 4.63M shares +408%
Weighted Average Number of Shares Outstanding, Diluted 4.63M shares +408%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 21.5M USD +66.2%
Cost of Revenue 8.66M USD +18.4%
Research and Development Expense 1.96M USD -29.1%
Selling and Marketing Expense 16.8M USD -31.5%
General and Administrative Expense 10M USD -8.33%
Operating Income (Loss) -15.9M USD +63.5%
Nonoperating Income (Expense) 8.14M USD -65%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.79M USD +61.8%
Income Tax Expense (Benefit) -4.68M USD
Net Income (Loss) Attributable to Parent -7.79M USD +61.8%
Earnings Per Share, Basic -0.52 USD/shares -101%
Earnings Per Share, Diluted -0.52 USD/shares -101%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.62M USD -41%
Accounts Receivable, after Allowance for Credit Loss, Current 4.81M USD +54.1%
Inventory, Net 3.75M USD +69.5%
Assets, Current 12M USD +9.91%
Property, Plant and Equipment, Net 50K USD -66.9%
Operating Lease, Right-of-Use Asset 335K USD -46.7%
Other Assets, Noncurrent 238K USD -88.2%
Assets 12.6M USD -7.94%
Accounts Payable, Current 12.6M USD +21.8%
Employee-related Liabilities, Current 908K USD -39.9%
Accrued Liabilities, Current 8.44M USD +33.8%
Liabilities, Current 21.4M USD +15.9%
Operating Lease, Liability, Noncurrent 100K USD -78.5%
Liabilities 22.9M USD -0.85%
Retained Earnings (Accumulated Deficit) -422M USD -1.88%
Stockholders' Equity Attributable to Parent -10.3M USD -9.43%
Liabilities and Equity 12.6M USD -7.94%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.48M USD -55.2%
Net Cash Provided by (Used in) Financing Activities 2.54M USD +226%
Net Cash Provided by (Used in) Investing Activities -133K USD -100%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 6.86M shares +636%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 59K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.62M USD -41%
Interest Paid, Excluding Capitalized Interest, Operating Activities 50K USD -46.8%
Deferred Tax Assets, Valuation Allowance 100M USD +4.05%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 100M USD +4.05%
Operating Lease, Liability 378K USD -46.6%
Depreciation 26K USD 0%
Payments to Acquire Property, Plant, and Equipment 133K USD -50.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -14.5M USD +43.1%
Lessee, Operating Lease, Liability, to be Paid 399K USD -49.6%
Property, Plant and Equipment, Gross 253K USD 0%
Operating Lease, Liability, Current 378K USD +14.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 101K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 298K USD -24.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21K USD -74.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 101K USD -74.6%
Deferred Tax Assets, Operating Loss Carryforwards 88.3M USD +1.22%
Preferred Stock, Shares Issued 4.85K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 87K USD +13%
Additional Paid in Capital 412M USD +1.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 333K USD -33.1%
Interest Expense 1.2M USD -54.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%